Open Access
| Numéro |
Radioprotection
Volume 60, Numéro 3, Juillet-Septembre 2025
|
|
|---|---|---|
| Page(s) | 277 - 284 | |
| DOI | https://doi.org/10.1051/radiopro/2025005 | |
| Publié en ligne | 15 septembre 2025 | |
- Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S, Schäfers M. 2015. Essler Early side effects and first results of radioligand therapy with 177 Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5: 1. [Google Scholar]
- Alnaaimi M, Sulieman A, Alkhorayef M, Salah H, Alduaij M. 2021. Organs dosimetry in targeted radionuclide therapy. Radiat Phys Chem 188: 109668. [Google Scholar]
- Capala J, Graves S, Scott A, Sgouros G, James S, Zanzonico P, Zimmerman BE. 2021. Dosimetry for radiopharmaceutical therapy: current practices and commercial resources. J Nucl Med 62: 3. [Google Scholar]
- Carneiro LG, de Lucena EA, da Silva Sampaio C, Dantas AL, Sousa WO, Santos MS, Dantas BM. 2015. Internal dosimetry of nuclear medicine workers through the analysis of 131I in aerosols. Appl Radiat Isotopes 1: 70. [Google Scholar]
- Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J. 2010. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 21: 787. [Google Scholar]
- Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, et al. 2014. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas 43: 518. [Google Scholar]
- Goddu SM. 1997. MIRD cellular S values: Self-absorbed dose per unit cumulated activity for selected radionuclides and monoenergetic electron and alpha particle emitters incorporated into different cell compartments. Society of Nuclear Medicine Vol. 1, Part2, Chap. 3, p. 150 [Google Scholar]
- Huizing DM, Verheij M, Stokkel MP. 2018. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res. 8: 1. [Google Scholar]
- Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. 2011. Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y-DOTATATE and tandem 90 Y/177 Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imag 38: 1788. [Google Scholar]
- Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. 2011. Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y-DOTATATE and tandem 90 Y/177 Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Molec Imag 38: 1788. [Google Scholar]
- Lassmann M, Eberlein U, Gear J, Konijnenberg M, Kunikowska J. 2021. Dosimetry for radiopharmaceutical therapy: the European perspective. J Nucl Med 62: 737. [Google Scholar]
- Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K., 2016. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med 57: 151. [Google Scholar]
- Mattsson S. 2015. Patient dosimetry in nuclear medicine. Radiat Protect Dosimetry 165: 416. [Google Scholar]
- Mittra ES. 2018. Neuroendocrine tumor therapy: 177Lu-DOTATATE. Am J Roentgenol 211: 278. [Google Scholar]
- Panta RK, Segars P, Yin FF, Cai J. 2012. Establishing a framework to implement 4D ICRP phantom for 4D radiotherapy research. J Cancer Res Therapeut 8: 565. [Google Scholar]
- Parach AA, Rajabi H, Askari MA. 2011. Assessment of MIRD data for internal dosimetry using the GATE Monte Carlo code. Radiat Environ Biophys 50: 441. [Google Scholar]
- Pinto GM, Bonifacio DA, de Sá LV, Lima LFC, Vieira IF, Lopes RT. 2020. A cell-based dosimetry model for radium-223 dichloride therapy using bone micro-CT images and GATE simulations. Phys Med Biol 65: 450. [Google Scholar]
- Potter CA. 2024. Internal dosimetry—a review. Health Phys 87: 455. [Google Scholar]
- Pasquier JL, Bourguignon M, Bertho JM. 2011. Une dialectique récurrente: des dangers aux risques des expositions aux rayonnements ionisants. Radioprotection. 2024 Dec 13;59: 250. [Google Scholar]
- Sandström M, Garske-Román U, Johansson S, Granberg D, Sundin AN. 2018. Freedman Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta Oncol 57: 516. [Google Scholar]
- Segars WP, Tsui BM, Cai J, Yin FF, Fung GS, Samei E. 2017. Application of the 4-D XCAT phantoms in biomedical imaging and beyond. IEEE Trans Med Imag 10: 680. [Google Scholar]
- Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, De Braud F, Buzzoni R, Milione M, Lorenzoni A, Bogni A. 2014. Treatment with tandem [90 Y] DOTA-TATE and [177 Lu] DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imag 41: 223. [Google Scholar]
- Sowa-Staszczak A, Pach D, Kunikowska J, Krolicki L, Stefanska A, Tomaszuk M, Buziak-Bereza M, Mikolajczak R, Matyja M, Gilis-Januszewska A, Jabrocka-Hybel A. 2011. Efficacy and safety of 90 Y-DOTATATE therapy in neuroendocrine tumours. Endokrynol. Polska 62: 392. [Google Scholar]
- Thiam C, Breton V, Donnarieix D, Habib B, Maigne L. 2008. Validation of a dose deposited by low-energy photons using GATE/GEA NT4. Phys Med Biol 53: 3039. [Google Scholar]
- Veress AI, Segars WP, Tsui BM. 2010. Gullberg Incorporation of a left ventricle finite element model defining infarction into the ICRP imaging phantom. IEEE Trans Med Imag 30: 915. [Google Scholar]
- Villoing D, Marcatili S, Garcia M, Bardiès M. 2017. Internal dosimetry with the Monte Carlo code GATE: validation using the ICRP/ICRU female reference computational model. Phys Med Biol 62: 1885. [Google Scholar]
- Zemczak A, Gut P, Pawlak D, Kołodziej M, Królicki L, Kos-Kudła B, Ruchała M, Kamiński G, Kunikowska J. 2021. The safety and efficacy of the repeated PRRT with [90Y] Y/[177Lu] Lu-DOTATATE in patients with NET. Int J Endocrinol 23: 2021. [Google Scholar]
- Zweit J. 1996. Radionuclides and carrier molecules for therapy. Phys Med Biol 41: 1905. [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.